Answers are grounded in this paper and cite their sources.
Hashimoto's thyroiditis (HT) is an autoimmune disease marked by chronic inflammation and degeneration of the thyroid gland that affects approximately 7.5% of the global population. HT has been strongly linked to an increased risk of miscarriage in pregnant women. Current treatments for HT are limited to restoring lost thyroid hormone function through thyroid hormone replacement; however, although effective at addressing metabolic related issues, these treatments have been largely ineffective at reducing the risk of miscarriage in these patients. HT is characterized by an imbalance of pro- and anti-inflammatory immune responses, resulting in a dysregulation of the maternal immune response that can cause intolerance of the fetus, contributing to miscarriage. Specifically, HT is marked by elevated pro-inflammatory factors, such as interferon-gamma (INF-g) and tumor necrosis factor-alpha (TNF-a), and decreased anti-inflammatory factors, such as regulatory cells and interleukin-10 (IL-10). Butyrate is a short-chain fatty acid found in the gut and has demonstrated anti-inflammatory effects through upregulation of IL-10 production and regulating the activity of T and B cells. Animal and human studies have supported butyrate's therapeutic effects and its safe administration in both pregnant and non-pregnant individuals. Accordingly, we hypothesize that butyrate supplementation in women with HT may reduce the risk of miscarriage, by regulating the imbalance of inflammatory factors. If validated, butyrate supplementation could act as a non-invasive and accessible treatment that mitigates the autoimmune mechanistic contributions of HT to the risk of miscarriage.
No takes yet. Share an insight, caveat, or question.
Rock et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: